172 Matching Annotations
  1. Aug 2022
  2. Apr 2022
    1. Amy Maxmen, PhD. (2020, August 26). 🙄The CDC’s only substantial communication with the public in the pandemic is through its MMW Reports. But the irrelevant & erroneous 1st line of this latest report suggests political meddling to me. (The WHO doesn’t declare pandemics. They declare PHEICs, which they did Jan 30) https://t.co/Y1NlHbQIYQ [Tweet]. @amymaxmen. https://twitter.com/amymaxmen/status/1298660729080356864

    1. ReconfigBehSci. (2020, November 3). As debate on ‘saving the economy versus saving lives’ marches on, it’s worth noting that this type of contrast actually has a name in fallacy research: Https://t.co/N8U4ABWTuh it’s also worth noting that there is now a substantial number of research articles on the topic. 1/n [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1323603017179013130

    1. Miguel Hernán. (2021, February 15). To all who claim that there’s no evidence that #SARSCoV2 is transmitted in bars: If the risk of transmitting #SARSCoV2 is provenly greater in crowded indoor places, why should bars be magically protected? Burden of the proof is on bar’s owners, not on scientists @BillHanage [Tweet]. @_MiguelHernan. https://twitter.com/_MiguelHernan/status/1361463022187864066

    1. Moritz Gerstung. (2021, November 1). An update on currently circulating SARS-CoV-2 variants in England beyond AY.4.2. Based on data released weekly to http://covid19.sanger.ac.uk we’ve been monitoring the speed of spread of currently 232 lineages. It’s a very dynamic situation and at times hard to stay on top. 🧵 [Tweet]. @MoritzGerstung. https://twitter.com/MoritzGerstung/status/1455136551407689734

  3. Mar 2022
  4. Jan 2022
  5. Dec 2021
  6. Nov 2021
    1. Eliminating Covid-19 seemed theoretically possible, because the original 2002 SARS virus ultimately disappeared.

      Eliminating SARS-CoV-2 was deemed plausible, because SARS-CoV-1 had been eliminated.

  7. Oct 2021
    1. Barros-Martins, J., Hammerschmidt, S. I., Cossmann, A., Odak, I., Stankov, M. V., Morillas Ramos, G., Dopfer-Jablonka, A., Heidemann, A., Ritter, C., Friedrichsen, M., Schultze-Florey, C., Ravens, I., Willenzon, S., Bubke, A., Ristenpart, J., Janssen, A., Ssebyatika, G., Bernhardt, G., Münch, J., … Behrens, G. M. N. (2021). Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nature Medicine, 1–5. https://doi.org/10.1038/s41591-021-01449-9

  8. Sep 2021
  9. Aug 2021
    1. Hillus, David, Tatjana Schwarz, Pinkus Tober-Lau, Hana Hastor, Charlotte Thibeault, Stefanie Kasper, Elisa T. Helbig, et al. “Safety, Reactogenicity, and Immunogenicity of Homologous and Heterologous Prime-Boost Immunisation with ChAdOx1-NCoV19 and BNT162b2: A Prospective Cohort Study,” June 2, 2021. https://doi.org/10.1101/2021.05.19.21257334.

    1. Prof. Devi Sridhar. “Rest of the World Watching Closely: ‘In Scotland, Estimated That 92.5% of Adults Would Have Tested Positive for Antibodies against SARS-CoV-2 on a Blood Test in the Week Beginning 12 July 2021’- Is This Enough to Dampen Transmission & Protect under 12s from Infection? Under 18s?” Tweet. @devisridhar (blog), August 4, 2021. https://twitter.com/devisridhar/status/1422852550957617157.

  10. Jul 2021
  11. Jun 2021
  12. May 2021
    1. .

      Since publication, the FDA has rescinded its authorisation of bamlanivimab (LY-CoV555), due to its lack of efficacy against circulating variants of concern, particularly B.1.351 (South African), as a result of E484K substitution A,B. Eli Lilly are now pursuing the use of their combination therapy of bamlanivimab with etesevimab (LY-CoV016).

      The antibody cocktail REGN-CoV2 showed sustained efficacy against tested variant strains and thus remains a viable treatment option. However, a mutational library scan by Starr et al. revealed that a single amino acid change (E406W) is all that is required for a future variant to escape this therapy C.

      Circulating variants highlight the limited efficacy of monoclonal antibodies to an evolving virus, particularly in those which are restricted to the RBD. A diverse panel of monoclonal antibodies, which bind subdominant epitopes may be a more sustainable approach.


      A – Wang, P et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. 2021. Nature. https://doi.org/10.1038/s41586-021-03398-2

      B – Starr, T.N.et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal LY-CoV555 and its cocktail with LY-CoV016. 2021. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2021.100255

      C – Starr, T.N.et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. 2021. Science. https://doi.org/10.1126/science.abf9302

  13. Apr 2021
    1. Acquiring viral drift sufficient to produce new influenza strains capable of escaping population immunity is believed to take years of global circulation, not weeks of local circulation.

      Experiencing enough viral drift to produce an influenza variant capable of escaping population immunity is believed to take years of global circulation (not weeks of local circulation).

  14. Mar 2021
    1. Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., Graham, B. S., Mascola, J. R., Chang, J. Y., Yin, M. T., Sobieszczyk, M., Kyratsous, C. A., Shapiro, L., Sheng, Z., Huang, Y., & Ho, D. D. (2021). Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature, 1–9. https://doi.org/10.1038/s41586-021-03398-2

  15. Feb 2021
    1. Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Lambson, B. E., Vermeulen, M., Berg, K. van den, Rossouw, T., Boswell, M., Ueckermann, V., Meiring, S., Gottberg, A. von, Cohen, C., Morris, L., Bhiman, J. N., & Moore, P. L. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. BioRxiv, 2021.01.18.427166. https://doi.org/10.1101/2021.01.18.427166

  16. Jan 2021
    1. Sadoff, J., Le Gars, M., Shukarev, G., Heerwegh, D., Truyers, C., de Groot, A. M., Stoop, J., Tete, S., Van Damme, W., Leroux-Roels, I., Berghmans, P.-J., Kimmel, M., Van Damme, P., de Hoon, J., Smith, W., Stephenson, K. E., De Rosa, S. C., Cohen, K. W., McElrath, M. J., … Schuitemaker, H. (2021). Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2034201

    1. This variant presents 14 non-synonymous mutations, 6 synonymous mutations and 3 deletions. The multiple mutations present in the viral RNA encoding for the spike protein (S) are of most concern, such as the deletion Δ69-70, deletion Δ144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
  17. Dec 2020
  18. Oct 2020
  19. Sep 2020
    1. Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., Chia, W. N., Chen, M. I.-C., Wang, L.-F., Ooi, E. E., Kalimuddin, S., Tambyah, P. A., Low, J. G.-H., Tan, Y.-J., & Bertoletti, A. (2020). SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature, 584(7821), 457–462. https://doi.org/10.1038/s41586-020-2550-z

  20. Aug 2020
    1. Amanat, F., White, K. M., Miorin, L., Strohmeier, S., McMahon, M., Meade, P., Liu, W.-C., Albrecht, R. A., Simon, V., Martinez‐Sobrido, L., Moran, T., García‐Sastre, A., & Krammer, F. (2020). An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening. Current Protocols in Microbiology, 58(1), e108. https://doi.org/10.1002/cpmc.108

  21. Jul 2020
  22. Jun 2020
  23. May 2020
    1. Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., Marrama, D., de Silva, A. M., Frazier, A., Carlin, A., Greenbaum, J. A., Peters, B., Krammer, F., Smith, D. M., Crotty, S., & Sette, A. (2020). Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell, S0092867420306103. https://doi.org/10.1016/j.cell.2020.05.015

  24. Apr 2020
    1. We investigated the biodistribution of SARS-CoV-2 among different tissues of inpatients with coronavirus disease 2019 (COVID-19)

      It would have been good to include 2-3 negative control samples in the data

    2. Four SARS-CoV-2 positive fecal specimens with high copy numbers were cultured
    1. Viruses have a direct connection to wastewater and drinking water purification when they are excreted in feces or urine

      How does this compare with spit and nasal secretions which also connect to the wastewater? Is this a bigger source of viral particles in the case of a respiratory virus?

  25. Mar 2020